Focus: REVOLUTION Medicines is a public biotech company focused on small-molecule oncology therapeutics across multiple tumor types including lung cancer, pancreatic cancer, and colorectal cancer. The company operates at clinical-stage with a diversified pipeline spanning Phase 1 through Phase 3 programs.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Hot — 445 jobs added in 30d
Net +360 (445 new, 85 removed). Aggressive expansion phase.
High-risk, high-reward opportunity for oncology specialists willing to bet on multiple late-stage programs, but cash runway and pre-commercialization maturity demand careful assessment.
Help build intelligence for REVOLUTION Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from REVOLUTION Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
symbol__ Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast CNN
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate - statnews.com
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate statnews.com
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ Stocktwits
Revolution Medicines Stock Surges on Promising Cancer Drug Data - IndexBox
Revolution Medicines Stock Surges on Promising Cancer Drug Data IndexBox
For pancreatic cancer patients, an exciting drug can feel out of reach - statnews.com
For pancreatic cancer patients, an exciting drug can feel out of reach statnews.com
Does Revolution Medicines’ pancreatic cancer drug have even greater potential? - statnews.com
Does Revolution Medicines’ pancreatic cancer drug have even greater potential? statnews.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo